双(2-噻吩)甲肟 | 10558-44-8

• 物质功能分类: 医药中间体 - 杂环化合物 - 噻吩类化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 杂芳族化合物
• 中文名称: 双(2-噻吩)甲肟
• 中文别名: 双(2-噻吩)酮肟；二-2-噻吩基酮肟
• 英文名称: bis(2-thienyl)methanone oxime
• 英文别名: bis(2-thienyl)ketoxime；2,2'-Dithienylketoxim；Di--ketoxim；Di(thiophen-2-yl)methanone oxime；N-(dithiophen-2-ylmethylidene)hydroxylamine
• CAS: 10558-44-8
• 化学式: C₉H₇NOS₂
• mdl: MFCD00173896
• 分子量: 209.293
• InChiKey: UXSSDPITEOFAMK-UHFFFAOYSA-N

物化性质

• 熔点：
  134 °C
• 沸点：
  361.1±30.0 °C(Predicted)
• 密度：
  1.38±0.1 g/cm3(Predicted)
• 稳定性/保质期：
  遵照规格使用和储存，则不会分解。

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  89.1
• 氢给体数：
  1
• 氢受体数：
  4

安全信息

• 危险品标志：
  Xi
• 危险类别码：
  R36/37/38
• 海关编码：
  2934999090
• 安全说明：
  S26,S37/39

SDS

Name:	Di2-thienylmethanone oxime 97% Material Safety Data Sheet
Synonym:	Bis-(thien-2-yl)ketone oxim
CAS:	10558-44-8

Section 1 - Chemical Product MSDS Name:Di2-thienylmethanone oxime 97% Material Safety Data Sheet
Synonym:Bis-(thien-2-yl)ketone oxim

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
10558-44-8	Di2-thienylmethanone oxime	97%	unlisted

Hazard Symbols: XI
Risk Phrases: 36/37/38

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Irritating to eyes, respiratory system and skin.
Potential Health Effects
Eye:
Causes eye irritation.
Skin:
Causes skin irritation. May be harmful if absorbed through the skin.
Ingestion:
May cause irritation of the digestive tract. May be harmful if swallowed.
Inhalation:
Causes respiratory tract irritation. May be harmful if inhaled.
Chronic:
Not available.

---

Section 4 - FIRST AID MEASURES
Eyes: Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.
Ingestion:
Get medical aid. Wash mouth out with water.
Inhalation:
Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid.
Notes to Physician:
Treat symptomatically and supportively.

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear.
Extinguishing Media:
Use water spray, dry chemical, carbon dioxide, or chemical foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container.

---

Section 7 - HANDLING and STORAGE
Handling:
Avoid breathing dust, vapor, mist, or gas. Avoid contact with skin and eyes.
Storage:
Store in a cool, dry place. Store in a tightly closed container.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 10558-44-8: Personal Protective Equipment Eyes: Not available.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Solid
Color: cream
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: 125 - 127 deg C
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C9H7NOS2
Molecular Weight: 209

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Not available.
Conditions to Avoid:
Incompatible materials.
Incompatibilities with Other Materials:
Oxidizing agents.
Hazardous Decomposition Products:
Nitrogen oxides, carbon monoxide, oxides of sulfur, carbon dioxide.
Hazardous Polymerization: Has not been reported

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 10558-44-8 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
Di2-thienylmethanone oxime - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
No information available.
IMO
No information available.
RID/ADR
No information available.

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: XI
Risk Phrases:
R 36/37/38 Irritating to eyes, respiratory system
and skin.
Safety Phrases:
S 26 In case of contact with eyes, rinse immediately
with plenty of water and seek medical advice.
S 37/39 Wear suitable gloves and eye/face
protection.
WGK (Water Danger/Protection)
CAS# 10558-44-8: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 10558-44-8 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 10558-44-8 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  双(2-噻吩)甲肟 在 氢氧化钾 、 sodium hydroxide 作用下， 以 乙醇 、 二甲基亚砜 为溶剂， 反应 0.5h， 生成 6-(Dithiophen-2-ylmethylideneamino)oxyhexanoic acid
  参考文献：
  名称：

  来自 6 - [[(二苯基亚甲基) 氨基] 氧基] 己酸的新型醛糖还原酶抑制剂

  摘要：

  从最近发现的醛糖还原酶抑制剂 6 - [[(二苯基亚甲基) 氨基] 氧基] 己酸 1 开始，进行了以下系统结构修改：(a) 苯环的形式取代，(b) 苯核心的等排取代通过杂芳烃吡啶和噻吩，(c) 芳族亚结构的形式还原和随后环己基环的缩小，(d) 在 C = N 和苯环之间引入亚甲基间隔基，最后 (e) 正式闭环分别得到三环芴酮、氧杂蒽酮和噻吨酮的衍生物。在这些系列中，带有二取代苯环的化合物 22-24 表现出最高的抑制活性（IC50 值约 3 μM），几乎处于参考 sorbinil 的范围内。

  DOI：

  10.1002/ardp.200600166
• 作为产物：
  描述：

  双(2-噻吩)酮 在 吡啶 、 盐酸羟胺 作用下， 以 乙醇 为溶剂， 反应 18.0h， 生成 双(2-噻吩)甲肟
  参考文献：
  名称：

  钯催化的丙烯酰胺（或炔烃）环肟肟的合成：菲啶和异喹啉的合成

  摘要：

  分子间插入：钯催化的多米诺aminopalladation / C  ħ官能序列已被开发，并提供访问官能菲啶和异喹啉（参见方案; TF =三氟甲磺酸酯，TMS =三甲基甲硅烷，MS =分子筛）。丁腈作为溶剂的使用决定了多米诺骨牌工艺的成功。

  DOI：

  10.1002/anie.200804683

文献信息

• 3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands
  申请人：Schering Corporation

  公开号：US20040106794A1

  公开（公告）日：2004-06-03

  There are disclosed compounds of the formula 1 or a pharmaceutically acceptable salt or solvate thereof which are useful for the treatment of chemokine-mediated diseases such as acute and chronic inflammatory disorders and cancer.

  这里公开了用于治疗诸如急性和慢性炎症性疾病以及癌症的趋化因子介导疾病的公式1化合物或其药用可接受的盐或溶剂。
• [EN] THIADIAZOLEDIOXIDES AND THIADIAZOLEOXIDES AS CXC- AND CC-CHEMOKINE RECEPTOR LIGANDS<br/>[FR] THIADIAZOLEDIOXYDES ET THIADIAZOLEOXIDES CONVENANT COMME LIGANDS DES RECEPTEURS DES CXC- ET CC-CHIMIOKINES
  申请人：PHARMACOPEIA INC

  公开号：WO2004033440A1

  公开（公告）日：2004-04-22

  Disclosed are novel compounds of the formula (IA) and the pharmaceutically acceptable salts and solvates thereof. Examples of groups comprising Substituent A include heteroaryl, aryl, heterocycloalkyl, cycloalkyl, aryl, alkynyl, alkenyl, aminoalkyl, alkyl or amino. Examples of groups comprising Substituent B include aryl and heteroaryl. Also disclosed is a method of treating a chemokine mediated diseases, such as, cancer, angiogenisis, angiogenic ocular diseases, pulmonary diseases, multiple sclerosis, rheumatoid arthritis, osteoarthritis, stroke and cardiac reperfusion injury, acute pain, acute and chronic inflammatory pain, and neuropathic pain using a compound of formula (IA).

  披露了公式（IA）的新颖化合物以及其中医药可接受的盐和溶剂化物。包含取代基A的基团示例包括杂芳基、芳基、杂环烷基、环烷基、芳基、炔基、烯基、氨基烷基、烷基或氨基。包含取代基B的基团示例包括芳基和杂芳基。还披露了一种治疗趋化因子介导的疾病的方法，例如，癌症、血管生成、血管生成性眼病、肺病、多发性硬化症、类风湿性关节炎、骨关节炎、中风和心脏再灌注损伤、急性疼痛、急性和慢性炎症性疼痛，以及使用公式（IA）的化合物的神经性疼痛。
• [EN] ISOTHIAZOLE DIOXIDES AS CXC- AND CC- CHEMOKINE RECEPTOR LIGANDS<br/>[FR] DIOXYDES D'ISOTHIAZOLE EN TANT QUE LIGANDS DU RECEPTEUR DE LA CHIMIOKINE CXC ET CC
  申请人：SCHERING CORP

  公开号：WO2005068460A1

  公开（公告）日：2005-07-28

  Disclosed are novel compounds of the formula (IA): and the pharmaceutically acceptable salts and solvates thereof. D and E are different groups wherein one is N and the other is CR50. Examples of groups comprising Substituent A include heteroaryl, aryl, heterocycloalkyl, cycloalkyl, aryl, alkynyl, alkenyl, aminoalkyl, alkyl or amino. Examples of groups comprising Substituent B include aryl and heteroaryl. Also disclosed is a method of treating a chemokine mediated diseases, such as, cancer, angiogenisis, angiogenic ocular diseases, pulmonary diseases, multiple sclerosis, rheumatoid arthritis, osteoarthritis, stroke and cardiac reperfusion injury, pain (e.g., acute pain, acute and chronic inflammatory pain, and neuropathic pain) using a compound of formula IA.

  公开了公式(IA)的新化合物：以及它们的药物可接受的盐和溶剂化物。D和E是不同的基团，其中一个是N，另一个是CR50。包含取代基A的基团示例包括杂芳基、芳基、杂环烷基、环烷基、芳基、炔基、烯基、氨基烷基、烷基或氨基。包含取代基B的基团示例包括芳基和杂芳基。还公开了一种治疗趋化因子介导的疾病的方法，例如，癌症、血管生成、血管生成性眼病、肺病、多发性硬化症、类风湿性关节炎、骨关节炎、中风和心肌再灌注损伤，疼痛(例如，急性疼痛、急性和慢性炎症性疼痛、神经性疼痛)使用公式IA的化合物。
• (Partial) agonist/antagonist properties of novel diarylalkyl carbamates on histamine H 3 receptors
  作者：Astrid Sasse、Holger Stark、Xavier Ligneau、Sigurd Elz、Sibylle Reidemeister、C.Robin Ganellin、Jean-Charles Schwartz、Walter Schunack

  DOI：10.1016/s0968-0896(00)00050-x

  日期：2000.5

  in a two-step reaction sequence from corresponding ketones. Some of the title compounds showed (partial) agonist activity at the histamine H3 receptor in vitro and in vivo. Diphenylmethyl carbamate 2 was identified as a new lead structure (ED50 = 5.3 +/- 2.6 mg/kg po, alpha = 1.0). Aromatic substitution in ortho- or para-positions of 2 led to a loss of agonist activity. meta-Substitution was tolerated

  在寻找组胺H 3受体的新配体时，合成了新的氨基甲酸二芳基烷基酯（1-19）作为3-（1H-咪唑-4-基）丙醇和-乙醇的衍生物。氨基甲酸酯是通过异氰酸酯通过与双光气反应从相应的胺或从相关的羧酸/二苯基磷酰基叠氮化物和醇组分中生成的。由两步反应，由相应的酮制备受阻胺。在体外和体内，一些标题化合物对组胺H3受体显示（部分）激动剂活性。氨基甲酸二苯甲基酯2被鉴定为新的铅结构（ED50 = 5.3 +/- 2.6 mg / kg po，alpha = 1.0）。2的邻位或对位的芳香取代导致激动剂活性降低。元替代在一定程度上是可以容忍的。这些作用似乎是由取代基的空间特性而非电子特性引起的。对杂环中一个或两个苯基环被杂环交换的研究导致了高活性和选择性的噻吩衍生物18（ED50 3.4 +/- 1.4 mg / kg po，α= 1.0）。组胺H3受体的这些新的（部分）激动剂可以用作研究H3受体的分子方面
• Photobase generating monomers: synthesis, evaluation and utilization for fabricating fluorescence patterns
  作者：Lanlan Liu、Jinbao Guo、Zihao Li、Jie Wei

  DOI：10.1039/c4ra00499j

  日期：——

  In this study, we fabricated four new photobase generating monomers, in which carbamate units functioned as the photobase generating moieties, methacrylate units served as the polymerizable groups and four different groups, succinimido, camphorquinone 3-oximino, di-2-thienyl ketoximino and difuril dioximino units, acted as photosensitive species. The effect of different photosensitive species on the photochemical behavior of the monomers was investigated in detail. The results demonstrate that, among the four monomers, succinimido methacryloxyethyl carbamate (SMC) exhibits the most stable photobase generating property. Furthermore, a copolymer containing SMC is used for a fluorescence imaging material. The fluorescence spectrum of the fluorescamine-treated irradiated copolymer film showed a strong fluorescence in the range of 420–650 nm with a fluorescence maximum at 476 nm. The patterns in the copolymer films exhibit very distinct fluorescence images with colors of blue, green and red at certain observation wavelengths.

  在本研究中，我们合成了四种新型光碱基生成单体，其中氨基甲酸酯单元作为光碱基生成基团，甲基丙烯酸酯单元作为可聚合基团，而琥珀酰亚胺、樟脑醌3-肟、二-2-噻吩酮肟和二呋喃二肟单元分别作为光敏物种。我们详细研究了不同光敏物种对单体光化学行为的影响。结果表明，在四种单体中，琥珀酰亚胺甲基丙烯酰氧乙基氨基甲酸酯（SMC）展现出最稳定的光碱基生成性能。此外，我们还利用含有SMC的共聚物制备了一种荧光成像材料。经荧光胺处理并照射后的共聚物薄膜在420-650 nm范围内呈现出强烈的荧光，最大荧光峰位于476 nm。共聚物薄膜中的图案在特定观测波长下显示出非常鲜明的蓝、绿、红三色荧光图像。